Home ETF List About

Portfolio Holdings Detail for ISIN IE00B3VWM098
Stock Name / FundiShares VII PLC - iShares MSCI USA Small Cap ESG Enhanced ETF USD Acc
IssuerBlackrock
Entity holding fund iShares VII Public Limited Company
Entity TypeUmbrella investment company with variable capital and having segregated liability between its funds
Entity LEI 549300Q7FFITMZ2PFZ28
ETF TickerCUS1(GBX) LSE
ETF TickerCUSS(USD) LSE
ETF TickerSXRG(EUR) F
ETF TickerCSUSS.MI(EUR) CXE
ETF TickerCSUSSz(USD) CXE
ETF TickerCUSS.LS(USD) CXE
ETF TickerCSUSS(EUR) ETF Plus
ETF TickerCUS1.L(GBP) LSE
ETF TickerCUSS.L(GBP) LSE

Holdings detail for PTCT

Stock NamePTC Therapeutics Inc
TickerPTCT(USD) NASDAQ
TYPECommon Stock
CountryUSA
ISINUS69366J2006
LEI549300UJLWOIWFDGB318

Show aggregate PTCT holdings

News associated with PTCT

Bank of America Issues Pessimistic Forecast for PTC Therapeutics (NASDAQ:PTCT) Stock Price
PTC Therapeutics (NASDAQ:PTCT – Free Report) had its price objective reduced by Bank of America from $82.00 to $76.00 in a research report released on Wednesday,Benzinga reports. They currently have a buy rating on the biopharmaceutical company’s stock. Several other brokerages have also issued reports on PTCT. Wall Street Zen lowered PTC Therapeutics from a […] - 2025-08-21 04:58:55
PTC Therapeutics (NASDAQ:PTCT) Price Target Lowered to $73.00 at Wells Fargo & Company
PTC Therapeutics (NASDAQ:PTCT – Free Report) had its price objective trimmed by Wells Fargo & Company from $79.00 to $73.00 in a research report released on Wednesday morning,Benzinga reports. The firm currently has an overweight rating on the biopharmaceutical company’s stock. Other equities analysts also recently issued reports about the company. Cantor Fitzgerald increased their […] - 2025-08-21 04:58:48
Noteworthy Monday Option Activity: ADBE, PTCT, RUM
Among the underlying components of the Russell 3000 index, we saw noteworthy options trading volume today in Adobe Inc (Symbol: ADBE), where a total of 32,627 contracts have traded so far, representing approximately 3.3 million underlying shares. That amounts to about 95.9% of - 2025-08-11 16:29:24
Natixis Advisors LLC Boosts Holdings in PTC Therapeutics, Inc. (NASDAQ:PTCT)
Natixis Advisors LLC increased its holdings in PTC Therapeutics, Inc. (NASDAQ:PTCT – Free Report) by 26.2% during the first quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 15,220 shares of the biopharmaceutical company’s stock after buying an additional 3,160 shares during the quarter. Natixis […] - 2025-08-11 05:47:02
PTC Therapeutics, Inc. (NASDAQ:PTCT) Given Average Rating of “Moderate Buy” by Brokerages
Shares of PTC Therapeutics, Inc. (NASDAQ:PTCT – Get Free Report) have been assigned an average recommendation of “Moderate Buy” from the fifteen ratings firms that are currently covering the firm, Marketbeat Ratings reports. One research analyst has rated the stock with a sell rating, four have given a hold rating, nine have issued a buy […] - 2025-08-11 05:11:00
PTC Therapeutics (NASDAQ:PTCT) Price Target Raised to $80.00
PTC Therapeutics (NASDAQ:PTCT – Free Report) had its price target lifted by UBS Group from $71.00 to $80.00 in a research note released on Tuesday,Benzinga reports. They currently have a buy rating on the biopharmaceutical company’s stock. PTCT has been the topic of several other reports. Citigroup increased their target price on shares of PTC […] - 2025-08-01 05:49:00
PTC Therapeutics (NASDAQ:PTCT) Price Target Raised to $120.00
PTC Therapeutics (NASDAQ:PTCT – Free Report) had its price objective lifted by Cantor Fitzgerald from $112.00 to $120.00 in a research note issued to investors on Tuesday,Benzinga reports. They currently have an overweight rating on the biopharmaceutical company’s stock. Cantor Fitzgerald also issued estimates for PTC Therapeutics’ FY2025 earnings at $8.16 EPS and FY2026 earnings […] - 2025-08-01 05:48:59
PTC Therapeutics, Inc. (NASDAQ:PTCT) Shares Sold by Y Intercept Hong Kong Ltd
Y Intercept Hong Kong Ltd lowered its holdings in PTC Therapeutics, Inc. (NASDAQ:PTCT – Free Report) by 54.8% during the first quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 4,981 shares of the biopharmaceutical company’s stock after selling 6,043 shares during the quarter. Y Intercept Hong […] - 2025-07-31 04:39:00
Truist Financial Issues Positive Forecast for PTC Therapeutics (NASDAQ:PTCT) Stock Price
PTC Therapeutics (NASDAQ:PTCT – Free Report) had its price objective increased by Truist Financial from $80.00 to $86.00 in a report published on Tuesday morning,Benzinga reports. Truist Financial currently has a buy rating on the biopharmaceutical company’s stock. PTCT has been the topic of a number of other research reports. Wells Fargo & Company lifted […] - 2025-07-30 05:06:48
Bank of America Forecasts Strong Price Appreciation for PTC Therapeutics (NASDAQ:PTCT) Stock
PTC Therapeutics (NASDAQ:PTCT – Free Report) had its price target increased by Bank of America from $68.00 to $84.00 in a research report released on Tuesday morning,Benzinga reports. The firm currently has a buy rating on the biopharmaceutical company’s stock. A number of other equities analysts have also weighed in on the company. Royal Bank […] - 2025-07-30 04:22:59
Barclays Forecasts Strong Price Appreciation for PTC Therapeutics (NASDAQ:PTCT) Stock
PTC Therapeutics (NASDAQ:PTCT – Free Report) had its price objective upped by Barclays from $42.00 to $46.00 in a report published on Tuesday,Benzinga reports. The brokerage currently has an equal weight rating on the biopharmaceutical company’s stock. Several other analysts also recently commented on PTCT. Robert W. Baird lowered their price objective on PTC Therapeutics […] - 2025-07-30 04:22:55
PTC Therapeutics (NASDAQ:PTCT) Shares Gap Up After Analyst Upgrade
PTC Therapeutics, Inc. (NASDAQ:PTCT – Get Free Report)’s stock price gapped up prior to trading on Tuesday after Truist Financial raised their price target on the stock from $80.00 to $86.00. The stock had previously closed at $44.34, but opened at $47.50. Truist Financial currently has a buy rating on the stock. PTC Therapeutics shares […] - 2025-07-30 02:35:02
New York State Common Retirement Fund Buys 2,000 Shares of PTC Therapeutics, Inc. (NASDAQ:PTCT)
New York State Common Retirement Fund boosted its stake in PTC Therapeutics, Inc. (NASDAQ:PTCT – Free Report) by 8.5% during the 1st quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 25,421 shares of the biopharmaceutical company’s stock after acquiring an additional 2,000 shares […] - 2025-07-25 05:44:49
Cerity Partners LLC Acquires Shares of 12,581 PTC Therapeutics, Inc. (NASDAQ:PTCT)
Cerity Partners LLC bought a new position in shares of PTC Therapeutics, Inc. (NASDAQ:PTCT – Free Report) during the 1st quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund bought 12,581 shares of the biopharmaceutical company’s stock, valued at approximately $641,000. A number of other institutional investors have […] - 2025-07-25 04:50:54
PTC Therapeutics, Inc. (NASDAQ:PTCT) Given Average Rating of “Moderate Buy” by Brokerages
PTC Therapeutics, Inc. (NASDAQ:PTCT – Get Free Report) has earned an average recommendation of “Moderate Buy” from the fifteen ratings firms that are covering the stock, Marketbeat Ratings reports. One equities research analyst has rated the stock with a sell recommendation, four have assigned a hold recommendation, nine have assigned a buy recommendation and one […] - 2025-07-22 03:29:02
PTC Therapeutics, Inc. (NASDAQ:PTCT) Holdings Cut by Bank of New York Mellon Corp
Bank of New York Mellon Corp lowered its stake in shares of PTC Therapeutics, Inc. (NASDAQ:PTCT – Free Report) by 0.2% in the first quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm owned 216,443 shares of the biopharmaceutical company’s stock after selling 439 shares during the period. […] - 2025-07-21 04:26:50
PTC Therapeutics, Inc. (NASDAQ:PTCT) Stock Position Decreased by Teacher Retirement System of Texas
Teacher Retirement System of Texas decreased its stake in shares of PTC Therapeutics, Inc. (NASDAQ:PTCT – Free Report) by 8.9% during the first quarter, HoldingsChannel.com reports. The fund owned 18,681 shares of the biopharmaceutical company’s stock after selling 1,830 shares during the period. Teacher Retirement System of Texas’ holdings in PTC Therapeutics were worth $952,000 […] - 2025-07-15 04:24:39
10,287 Shares in PTC Therapeutics, Inc. (NASDAQ:PTCT) Purchased by Allspring Global Investments Holdings LLC
Allspring Global Investments Holdings LLC bought a new position in shares of PTC Therapeutics, Inc. (NASDAQ:PTCT – Free Report) during the first quarter, HoldingsChannel reports. The institutional investor bought 10,287 shares of the biopharmaceutical company’s stock, valued at approximately $524,000. A number of other hedge funds have also recently bought and sold shares of PTCT. […] - 2025-07-11 04:31:12
PTC Therapeutics, Inc. (NASDAQ:PTCT) Shares Purchased by Diversified Trust Co
Diversified Trust Co boosted its holdings in shares of PTC Therapeutics, Inc. (NASDAQ:PTCT – Free Report) by 2.0% during the 1st quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 17,147 shares of the biopharmaceutical company’s stock after buying an additional 329 shares during the period. […] - 2025-06-30 05:10:54
PTC Therapeutics (NASDAQ:PTCT) Coverage Initiated at Truist Financial
Equities researchers at Truist Financial started coverage on shares of PTC Therapeutics (NASDAQ:PTCT – Get Free Report) in a research report issued to clients and investors on Tuesday, Marketbeat.com reports. The firm set a “buy” rating and a $80.00 price target on the biopharmaceutical company’s stock. Truist Financial’s target price points to a potential upside […] - 2025-06-19 02:42:49
Pallas Capital Advisors LLC Makes New $353,000 Investment in PTC Therapeutics, Inc. (NASDAQ:PTCT)
Pallas Capital Advisors LLC purchased a new stake in PTC Therapeutics, Inc. (NASDAQ:PTCT – Free Report) in the 1st quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor purchased 6,925 shares of the biopharmaceutical company’s stock, valued at approximately $353,000. Several other institutional […] - 2025-06-13 05:38:53
PTC Therapeutics, Inc. (NASDAQ:PTCT) Shares Purchased by GAMMA Investing LLC
GAMMA Investing LLC lifted its stake in PTC Therapeutics, Inc. (NASDAQ:PTCT – Free Report) by 9,393.9% during the 1st quarter, according to the company in its most recent filing with the SEC. The fund owned 48,514 shares of the biopharmaceutical company’s stock after acquiring an additional 48,003 shares during the quarter. GAMMA Investing LLC’s holdings […] - 2025-06-13 04:36:51
Universal Beteiligungs und Servicegesellschaft mbH Takes Position in PTC Therapeutics, Inc. (NASDAQ:PTCT)
Universal Beteiligungs und Servicegesellschaft mbH purchased a new stake in PTC Therapeutics, Inc. (NASDAQ:PTCT – Free Report) during the fourth quarter, according to its most recent Form 13F filing with the SEC. The fund purchased 108,345 shares of the biopharmaceutical company’s stock, valued at approximately $4,891,000. Universal Beteiligungs und Servicegesellschaft mbH owned 0.14% of PTC […] - 2025-06-02 06:10:57
Wells Fargo & Company Boosts PTC Therapeutics (NASDAQ:PTCT) Price Target to $74.00
PTC Therapeutics (NASDAQ:PTCT – Get Free Report) had its price target hoisted by equities research analysts at Wells Fargo & Company from $68.00 to $74.00 in a report released on Tuesday,Benzinga reports. The firm currently has an “overweight” rating on the biopharmaceutical company’s stock. Wells Fargo & Company‘s price target suggests a potential upside of […] - 2025-05-29 02:31:00
PTC Therapeutics, Inc. (NASDAQ:PTCT) Given Consensus Recommendation of “Moderate Buy” by Brokerages
PTC Therapeutics, Inc. (NASDAQ:PTCT – Get Free Report) has received a consensus recommendation of “Moderate Buy” from the fourteen ratings firms that are covering the stock, Marketbeat.com reports. One analyst has rated the stock with a sell recommendation, four have given a hold recommendation, eight have assigned a buy recommendation and one has assigned a […] - 2025-05-28 04:46:51
PTC Therapeutics (NASDAQ:PTCT) Shares Gap Up After Earnings Beat
PTC Therapeutics, Inc. (NASDAQ:PTCT – Get Free Report)’s share price gapped up prior to trading on Wednesday following a better than expected earnings announcement. The stock had previously closed at $36.19, but opened at $39.40. PTC Therapeutics shares last traded at $39.92, with a volume of 455,281 shares trading hands. The biopharmaceutical company reported $10.04 […] - 2025-05-09 02:20:49
Analysts Set PTC Therapeutics, Inc. (NASDAQ:PTCT) PT at $63.92
Shares of PTC Therapeutics, Inc. (NASDAQ:PTCT – Get Free Report) have earned an average rating of “Moderate Buy” from the fifteen brokerages that are presently covering the stock, MarketBeat reports. Two analysts have rated the stock with a sell rating, four have assigned a hold rating, eight have assigned a buy rating and one has […] - 2025-05-06 02:30:48
48,728 Shares in PTC Therapeutics, Inc. (NASDAQ:PTCT) Purchased by Raymond James Financial Inc.
Raymond James Financial Inc. acquired a new stake in PTC Therapeutics, Inc. (NASDAQ:PTCT – Free Report) during the fourth quarter, Holdings Channel reports. The firm acquired 48,728 shares of the biopharmaceutical company’s stock, valued at approximately $2,200,000. Several other institutional investors have also added to or reduced their stakes in the business. Smartleaf Asset Management […] - 2025-05-01 05:01:04
Federated Hermes Inc. Buys New Shares in PTC Therapeutics, Inc. (NASDAQ:PTCT)
Federated Hermes Inc. purchased a new position in shares of PTC Therapeutics, Inc. (NASDAQ:PTCT – Free Report) in the 4th quarter, HoldingsChannel.com reports. The institutional investor purchased 47,828 shares of the biopharmaceutical company’s stock, valued at approximately $2,159,000. A number of other hedge funds and other institutional investors have also recently modified their holdings of […] - 2025-04-14 05:15:06
PTC Therapeutics, Inc. (NASDAQ:PTCT) Position Reduced by Prudential Financial Inc.
Prudential Financial Inc. trimmed its position in PTC Therapeutics, Inc. (NASDAQ:PTCT – Free Report) by 5.5% in the fourth quarter, HoldingsChannel.com reports. The firm owned 5,620 shares of the biopharmaceutical company’s stock after selling 330 shares during the quarter. Prudential Financial Inc.’s holdings in PTC Therapeutics were worth $254,000 at the end of the most […] - 2025-04-11 05:03:01

iShares VII PLC - iShares MSCI USA Small Cap ESG Enhanced ETF USD Acc PTCT holdings

DateNumber of PTCT Shares HeldBase Market Value of PTCT SharesLocal Market Value of PTCT SharesChange in PTCT Shares HeldChange in PTCT Base ValueCurrent Price per PTCT Share HeldPrevious Price per PTCT Share Held
2025-11-12 (Wednesday)8,250PTCT holding decreased by -26USD 618,338PTCT holding increased by 7404USD 618,338-26USD 7,404 USD 74.9501 USD 73.82
2025-11-11 (Tuesday)8,276USD 610,934PTCT holding increased by 11090USD 610,9340USD 11,090 USD 73.82 USD 72.4799
2025-11-10 (Monday)8,276USD 599,844PTCT holding increased by 5793USD 599,8440USD 5,793 USD 72.4799 USD 71.78
2025-11-07 (Friday)8,276USD 594,051PTCT holding decreased by -6704USD 594,0510USD -6,704 USD 71.78 USD 72.59
2025-11-06 (Thursday)8,276PTCT holding decreased by -26USD 600,755PTCT holding increased by 4920USD 600,755-26USD 4,920 USD 72.59 USD 71.7701
2025-11-05 (Wednesday)8,302PTCT holding decreased by -260USD 595,835PTCT holding increased by 16016USD 595,835-260USD 16,016 USD 71.7701 USD 67.72
2025-11-04 (Tuesday)8,562PTCT holding decreased by -52USD 579,819PTCT holding decreased by -5330USD 579,819-52USD -5,330 USD 67.72 USD 67.93
2025-11-03 (Monday)8,614PTCT holding decreased by -52USD 585,149PTCT holding decreased by -6825USD 585,149-52USD -6,825 USD 67.93 USD 68.3099
2025-10-31 (Friday)8,666USD 591,974PTCT holding increased by 1733USD 591,9740USD 1,733 USD 68.3099 USD 68.11
2025-10-30 (Thursday)8,666USD 590,241PTCT holding increased by 6586USD 590,2410USD 6,586 USD 68.11 USD 67.35
2025-10-29 (Wednesday)8,666USD 583,655PTCT holding decreased by -1213USD 583,6550USD -1,213 USD 67.35 USD 67.49
2025-10-28 (Tuesday)8,666PTCT holding increased by 78USD 584,868PTCT holding increased by 8785USD 584,86878USD 8,785 USD 67.49 USD 67.08
2025-10-27 (Monday)8,588USD 576,083PTCT holding increased by 5840USD 576,0830USD 5,840 USD 67.08 USD 66.4
Share price and value of shares held is calculated on the adjusted close price of each day (row). Changes between days reflect the gain/loss of the portfolio as a result of changes in the adjusted close price and changes in the holdings

Share Trades of PTCT by Blackrock for IE00B3VWM098

Show aggregate share trades of PTCT

DateActionQuantityMarket HighMarket LowLikely Trade PriceLikely Trade Value (Profit/Loss)Average Price previous trades
2025-11-12SELL-26 74.950* 50.68 Profit of 1,318 on sale
2025-11-06SELL-2673.98071.360 71.622USD -1,862 50.22 Loss of -556 on sale
2025-11-05SELL-26073.80067.670 68.283USD -17,754 50.11 Loss of -4,725 on sale
2025-11-04SELL-5268.80066.215 66.473USD -3,457 50.02 Loss of -856 on sale
2025-11-03SELL-5269.17066.100 66.407USD -3,453 49.92 Loss of -857 on sale
2025-10-28BUY7867.49068.165 68.098USD 5,312 49.54
2025-10-24SELL-2666.40067.780 67.642USD -1,759 49.35 Loss of -476 on sale
2025-10-15BUY15668.51069.260 69.185USD 10,793 48.65
2025-10-02BUY2663.02063.330 63.299USD 1,646 48.47
2025-09-30BUY5261.37061.680 61.649USD 3,206 48.31
2025-09-11BUY10460.96061.110 61.095USD 6,354 47.97
2025-08-21SELL-2648.92049.230 49.199USD -1,279 47.97 Loss of -32 on sale
2025-07-31BUY7852.11052.700 52.641USD 4,106 47.94
2025-07-29SELL-2649.29050.490 50.370USD -1,310 47.91 Loss of -64 on sale
2025-06-30SELL-5248.84050.570 50.397USD -2,621 47.88 Loss of -131 on sale
2025-06-25SELL-2648.89049.435 49.381USD -1,284 47.85 Loss of -40 on sale
2025-06-20SELL-5250.20051.210 51.109USD -2,658 47.81 Loss of -172 on sale
2025-05-23BUY2645.93046.010 46.002USD 1,196 47.45
2025-05-19SELL-2646.96047.480 47.428USD -1,233 47.49 Profit of 2 on sale
2025-05-15SELL-7845.31046.820 46.669USD -3,640 47.52 Profit of 66 on sale
2025-05-12SELL-2646.01046.660 46.595USD -1,211 47.55 Profit of 25 on sale
2025-05-09SELL-2644.23046.030 45.850USD -1,192 47.58 Profit of 45 on sale
2025-04-30SELL-2649.84050.325 50.277USD -1,307 47.81 Loss of -64 on sale
2025-04-24SELL-5249.55050.390 50.306USD -2,616 47.74 Loss of -134 on sale
2025-04-17SELL-2647.39047.960 47.903USD -1,245 47.71 Loss of -5 on sale
2025-04-15SELL-7846.94048.600 48.434USD -3,778 47.73 Loss of -55 on sale
2025-04-14SELL-7845.08045.760 45.692USD -3,564 47.76 Profit of 161 on sale
2025-04-09SELL-10442.75044.070 43.938USD -4,570 47.96 Profit of 418 on sale
2025-04-07SELL-18242.82044.985 44.769USD -8,148 48.11 Profit of 609 on sale
2025-04-04SELL-26043.24046.160 45.868USD -11,926 48.17 Profit of 599 on sale
2025-03-31BUY2650.96052.890 52.697USD 1,370 48.15
2025-03-19SELL-5256.98057.420 57.376USD -2,984 47.30 Loss of -524 on sale
2025-03-14SELL-15654.50055.650 55.535USD -8,663 46.94 Loss of -1,341 on sale
2025-03-13SELL-5252.76054.650 54.461USD -2,832 46.86 Loss of -395 on sale
2025-03-12SELL-88453.61053.760 53.745USD -47,511 46.76 Loss of -6,174 on sale
2025-03-07SELL-5252.59053.790 53.670USD -2,791 46.50 Loss of -373 on sale
2025-03-06SELL-7852.80052.830 52.827USD -4,121 46.40 Loss of -501 on sale
2025-03-03SELL-2652.87055.600 55.327USD -1,439 46.12 Loss of -239 on sale
2025-02-28SELL-9,27855.26055.410 55.395USD -513,955 45.97 Loss of -87,445 on sale
2025-02-26SELL-5150.96051.750 51.671USD -2,635 45.81 Loss of -299 on sale
2025-02-25SELL-15350.36050.580 50.558USD -7,735 45.73 Loss of -739 on sale
2025-02-18BUY25549.44052.950 52.599USD 13,413 45.31
2025-02-13BUY5149.67049.980 49.949USD 2,547 44.96
2025-02-12BUY5148.93048.990 48.984USD 2,498 44.88
2025-02-11BUY15348.63549.650 49.549USD 7,581 44.80
2025-02-06BUY45949.79050.740 50.645USD 23,246 44.47
2025-01-27BUY5146.07047.290 47.168USD 2,406 43.88
2024-12-30BUY25545.77045.950 45.932USD 11,713 43.61
2024-12-06BUY20448.04049.440 49.300USD 10,057 43.10
2024-12-05BUY5148.40049.500 49.390USD 2,519 42.92
2024-12-04BUY25549.86051.620 51.444USD 13,118 42.67
2024-11-29BUY25543.88045.375 45.226USD 11,533 41.94
2024-11-27BUY20445.11047.230 47.018USD 9,592 41.67
2024-11-26BUY5146.01047.240 47.117USD 2,403 41.47
2024-11-21BUY25542.89043.410 43.358USD 11,056 41.22
2024-11-20BUY15341.96042.790 42.707USD 6,534 41.18
2024-11-18BUY61239.23039.860 39.797USD 24,356 41.42
2024-11-12BUY40044.62044.870 44.845USD 17,938 41.21
2024-11-08BUY25044.28046.550 46.323USD 11,581 40.99
2024-11-07BUY75042.96044.560 44.400USD 33,300 40.84
2024-11-06BUY10043.18043.270 43.261USD 4,326 40.64
2024-10-31BUY5039.92041.070 40.955USD 2,048 40.75
Market high and low price is on the date.

* (if shown) = market close price used not a projected price. This is used when we do not have market data available to calculate a projection

The likely trade price/value is our estimate on the likely price the trade took place at and is not the actual trade price. The likely LOSS/GAIN is our estimate. Where a profit/loss value is shown in the Likely Trade Value column, this is derived from matching trades between periods eg the most recent previous BUY is matched with the SELL for the same number of shares and the difference between the likely BUY price and likely SELL price is calculated. Where a profit or loss is shown in the Average Price of Previous Trades column, this is dervied using the likely trade price compared to the average of previous trades based on adjusted close

Shorting History of PTCT

DateShorted VolumeShort Exempt VolumeTotal Shares Traded% Shorted
2025-09-19134,8970383,22335.2%
2025-09-18283,3490426,43866.4%
2025-09-171,027,79401,194,00886.1%
2025-09-16193,3750307,40362.9%
2025-09-15322,7199534,13960.4%
2025-09-12385,45374562,96568.5%
2025-09-11284,2840452,60662.8%
2025-09-10278,5554408,67368.2%
2025-09-09468,2780688,80568.0%
2025-09-08283,8270420,01767.6%
2025-09-05346,6620658,62852.6%
2025-09-04461,6161,570706,32765.4%
2025-09-03500,00450703,68571.1%
2025-09-02410,808361623,97565.8%
2025-08-29260,928500368,01170.9%
2025-08-28169,3760286,54559.1%
2025-08-27117,5570225,79352.1%
2025-08-26159,7560292,41254.6%
2025-08-25184,3883278,80266.1%
2025-08-22212,2920337,12163.0%
2025-08-21110,0900199,27855.2%
2025-08-20214,8640342,11162.8%
2025-08-19574,175771,073,50653.5%
2025-08-18264,556175600,47344.1%
2025-08-15276,2360451,33761.2%
2025-08-14261,1060447,80158.3%
2025-08-13429,1970681,30463.0%
2025-08-12174,7390313,20955.8%
2025-08-11186,8746,675467,51140.0%
2025-08-08428,3251,746852,88150.2%
2025-08-07147,599144300,02149.2%
2025-08-0682,60020193,16742.8%
2025-08-05182,572112369,25749.4%
2025-08-04134,4690278,38048.3%
2025-08-01173,4700295,78658.6%
2025-07-31371,85250836,67944.4%
2025-07-30349,32275666,75252.4%
2025-07-29539,0072581,083,83649.7%
2025-07-28238,8930371,80364.3%
2025-07-25273,7870463,68359.0%
2025-07-2495,24840211,84045.0%
2025-07-23117,8270221,68053.2%
2025-07-22199,7160323,57861.7%
2025-07-21108,8530162,43967.0%
2025-07-18122,0370172,36370.8%

The data here is derived from FINRA daily shorted trade data. The Daily Short Sale Volume is the total volume of short trades that meet certain criteria on each trade date by 6 PM ET on the trade date. The detail trade data is derived from the monthly shorted trade data which will differ in aggregate. The detail trade data is derived from the transaction level data and includes ALL trades (including exempt) and the aggregation period extends beyond 6pm.

Back to Listing

Disclaimer

All information is provided as is without warranty and should be used for indicative purposes only. You should independently check data before making any investment decision. This information is derived from third party sources and we cannot guarantee that their data is current, accurate, complete, free from defects etc and we therefore accept no responsibility for how it may be used. We accept no liability for the reliability or accuracy of the data provided. We are not making recommendations for any financial instruments listed on this website.